Article

IOP-lowering drug a versatile choice in large-scale study

Houston-Once-daily bimatoprost 0.03% (Lumigan, Allergan) is a highly effective, safe, and well-accepted IOP-lowering medication across the di-verse population of patients encountered in daily practice, according to the results of a large-scale, com-munity-based, pro-spective, open-label study.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.